Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

NCT01735630 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.

NCT NCT01735630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01735630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Lead sponsor
OPKO Health, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2012
Completion date
May 31, 2015
Enrollment
350 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease